Abstract
Clinical and hematological features are presented for 261 patients with identified β-thalassemia (β-thal) mutations. Mutations causing Hb S [β6(A3)Glu→Val]-β0-thal were IVS-II-849 (A>G) in 44%, frameshift codon (FSC) 6 (–A) in 14%, Hb Monroe [β30(B12)Arg→Thr] in 14%, and IVS-II-1 (G>A) in 10%. Mutations causing Hb S-β+-thal with 14-25% Hb A (type III) were –29 (A>G) mutation in 60%, –88 (C>T) in 22% and the polyadenylation signal site (polyA) (T>C) mutation in 14%, and in Hb S-β+-thal with 1-7% Hb A (type I), all had the IVS-I-5 (G>C) mutation. Hematologically, only minor differences occurred between the four Hb S-β0-thal mutations, but among the three mutations causing Hb S-β+-thal type III, levels of Hb A2, Hb F, hemoglobin (Hb), MCV and MCH were highest in the –88 and lowest in the polyA mutations. Clinically, Hb S-β0-thal and Hb S-β+-thal type I were generally severe, and Hb S-β+-thal type III disease with the –88 mutation was milder than that caused by the polyA mutation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
